AU2021388832A1 - Stable formulations for radionuclide complexes - Google Patents

Stable formulations for radionuclide complexes Download PDF

Info

Publication number
AU2021388832A1
AU2021388832A1 AU2021388832A AU2021388832A AU2021388832A1 AU 2021388832 A1 AU2021388832 A1 AU 2021388832A1 AU 2021388832 A AU2021388832 A AU 2021388832A AU 2021388832 A AU2021388832 A AU 2021388832A AU 2021388832 A1 AU2021388832 A1 AU 2021388832A1
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
ascorbic acid
salt
radiolabeling
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021388832A
Other languages
English (en)
Inventor
Elena Maria ANDREOLLI
Luke HEAMES
Oliver LEIB
Sebastian MARX
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Itm Solucin GmbH
Original Assignee
Itm Solucin GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Itm Solucin GmbH filed Critical Itm Solucin GmbH
Publication of AU2021388832A1 publication Critical patent/AU2021388832A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2021388832A 2020-11-25 2021-11-24 Stable formulations for radionuclide complexes Pending AU2021388832A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2020/083363 WO2022111800A1 (en) 2020-11-25 2020-11-25 Stable formulations for radionuclide complexes
AUPCT/EP2020/083363 2020-11-25
PCT/EP2021/082812 WO2022112323A1 (en) 2020-11-25 2021-11-24 Stable formulations for radionuclide complexes

Publications (1)

Publication Number Publication Date
AU2021388832A1 true AU2021388832A1 (en) 2023-06-08

Family

ID=73598128

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021388832A Pending AU2021388832A1 (en) 2020-11-25 2021-11-24 Stable formulations for radionuclide complexes

Country Status (8)

Country Link
US (2) US20240374732A1 (https=)
EP (1) EP4251213A1 (https=)
JP (1) JP2023552180A (https=)
KR (1) KR20230134472A (https=)
CN (1) CN116806144A (https=)
AU (1) AU2021388832A1 (https=)
CA (1) CA3171753A1 (https=)
WO (2) WO2022111800A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4178628A4 (en) 2020-07-13 2025-04-02 Point Biopharma, Inc. RADIOPHARMACEUTICALS AND PROCEDURES
US11541134B1 (en) 2021-08-02 2023-01-03 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof
JP2025505307A (ja) * 2022-03-02 2025-02-21 ポイント・バイオファーマ・インコーポレイテッド 放射性医薬品及び方法
US20250099634A1 (en) 2023-09-25 2025-03-27 Novartis Ag Method of treating cancer
WO2025255398A1 (en) * 2024-06-05 2025-12-11 Ariceum Therapeutics Gmbh Radiopharmaceutical composition and methods
US12343409B1 (en) * 2024-06-05 2025-07-01 Ariceum Therapeutics Gmbh Radiopharmaceutical composition and methods
CN120733077B (zh) * 2025-09-01 2025-12-05 杭州景嘉航生物医药科技有限公司 药物组合物及其制备方法与药物制剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5139678B2 (ja) * 2003-07-24 2013-02-06 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 安定な放射性医薬品組成物およびその製法
AU2012294639B2 (en) 2011-08-05 2017-10-26 Molecular Insight Pharmaceuticals, Inc. Radiolabeled prostate specific membrane antigen inhibitors
PL2970345T3 (pl) 2013-03-15 2019-12-31 Cancer Targeted Technology Llc Znakowane 18F środki do obrazowania PET ukierunkowane na PSMA
EP2862857A1 (en) 2013-10-18 2015-04-22 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP3456700A1 (en) 2013-10-18 2019-03-20 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
CA3060143A1 (en) 2017-05-24 2018-11-29 Itm Isotopen Technologien Munchen Ag Novel psma-binding agents and uses thereof
US10756278B2 (en) 2017-07-18 2020-08-25 Purdue Research Foundation In situ thermal control of langmuir-schaefer transfer
US10596278B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
WO2020108753A1 (en) 2018-11-28 2020-06-04 ITM Isotopen Technologien München AG Novel tumor antigen binding agents and uses thereof

Also Published As

Publication number Publication date
WO2022111800A1 (en) 2022-06-02
JP2023552180A (ja) 2023-12-14
WO2022112323A1 (en) 2022-06-02
KR20230134472A (ko) 2023-09-21
US20240374732A1 (en) 2024-11-14
CN116806144A (zh) 2023-09-26
CA3171753A1 (en) 2022-06-02
US12605447B2 (en) 2026-04-21
US20250170243A1 (en) 2025-05-29
EP4251213A1 (en) 2023-10-04

Similar Documents

Publication Publication Date Title
US12605447B2 (en) Stable formulations for radionuclide complexes
ES3011272T3 (en) Dual mode radiotracer and -therapeutics
Sarko et al. Bifunctional chelators in the design and application of radiopharmaceuticals for oncological diseases
KR102934560B1 (ko) 신장 보호 물질로서의 파라-아미노히푸르산(pah)
KR20220063214A (ko) Grpr 길항제의 방사성표지 방법 및 이의 키트
EP4065176B1 (en) Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer
CA3171718C (en) Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer
WO2025218931A1 (en) Stable formulations comprising 225-actinium labeled complexes and methods for preparing the same
RU2842991C1 (ru) Комбинация пара-аминогиппуровой кислоты (паг) и меченных радиоактивным изотопом комплексов, предназначенная для лечения рака
RU2804349C2 (ru) Парааминогиппуровая кислота (паг) как вещество для защиты почек
HK40078095A (en) Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer
HK40078095B (en) Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer
RU2787105C2 (ru) Новые пса-связывающие агенты и их применение
HK40065088A (en) Para-aminohippuric acid (pah) as a renal protective substance
HK40065088B (en) Para-aminohippuric acid (pah) as a renal protective substance